

## **Acthar Ophthalmology Start Form**

Please complete Start Form and fax toll-free FAX: 1-877-221-9505 TEL: 1-877-463-8803

Faxed prescriptions will be accepted only from a prescribing practitioner. Patients must bring an original prescription to the pharmacy. Prescribers are reminded patients may choose any pharmacy of their choice.

DATE MEDICATION NEEDED:		SHIP TO: 🗅 Patient's Home 🗅 Prescriber's C	Office Injection training?				
1. PROVIDER INFORMATION							
PROVIDER NAME  SPECIALTY: NEPHROLOGY NEUROLOGY	NPI#  ☐ PULMONOLOGY ☐ RHEUMATOLOGY ☐ OPHTI						
FACILITY NAME	TELEPHONE	IF OTHER PLEASE INDICATE	:				
ADDRESS	CITY	STATE	ZIP				
OFFICE CONTACT NAME	CONTACT TELEPHONE	EMAIL ADDRESS	PREFERRED METHOD OF COMMUNICATION				
2. PATIENT INFORMATION							
PATIENT FIRST NAME PATIENT MII	IDDLE INITIAL PATIENT LAST NAME		DATE OF BIRTH GENDER				
HOME ADDRESS		CITY	STATE ZIP				
SHIPPING ADDRESS (IF NOT HOME ADDRESS)		CITY	STATE ZIP				
TELEPHONE	ALTERNATE TELEPHONE	BEST TIME TO CALL	PREFERRED LANGUAGE IF NOT ENGLISH				
EMAIL ADDRESS	PATIENT REPRESENTATIVE	RELATIONSHIP	TELEPHONE				
KNOWN ALLERGIES:		_ DIAGNOSIS CODE:					
3. INSURANCE INFORMATION (	PLEASE FAX FRONT AND BACK CO	PY OF ALL INSURANCE CARDS (F	PRESCRIPTION AND MEDICAL)				
PHARMACY BENEFITS		SUBSCRIBER ID #	GROUP # TEL #				
PRIMARY MEDICAL INSURANCE	POLICY HOLDER /RELATIONSHIP	SUBSCRIBER ID #	GROUP # TEL #				
4. PRESCRIPTION: H.P. ACTHAI	R® GEL NDC# 6	33004-8710-1 5 mL multidose via	al containing 80 USP units per mL				
INITIATE PATIENT WITH:							
DOSE: ML SCHEDULE/FREQUENCY:	QUANTITY OF	5 ML MULTIDOSE VIALS: REFILLS:	☐ INTRAMUSCULAR ROUTE OF ADMINISTRATION: ☐ SUBCUTANEOUS				
ADDITIONAL SPECIAL INSTRUCTIONS, OR TAPER DO	OSE, IF APPLICABLE:	·					
SUPPLIES: SYRINGE SIZE: 1 cc 3 cc (other) QUANTITY: NEEDLE SIZE: 20 g needle, 1 inch 23 g needle, 1 inch 25 g needle, 1 inch 25 g needle, 5/8 inch (other): QUANTITY:							
OTHER SUPPLIES:REFILLS:							
HOME INJECTION TRAINING SERVICES FOR ADULT PATIENTS  By initialing here (original required) I request that company-funded home injection training services be arranged for my patient. I understand that home injection training services is for one instruction visit only and NOT a home health nursing service. I also understand that all reasonable efforts will be made to schedule the home injection training services visit within 24 hours of the patient's receipt of drug shipment.							
INITIALS	DATE						
5. PATIENT AUTHORIZATION(S)							
Patient Authorization and Registration for optional supplemental education and support programs available for patients prescribed Acthar  Mallinckrodt provides ongoing education and support for patients whose healthcare providers have determined that Acthar is the appropriate clinical therapy for their patients. Check the appropriate box(es)							
and sign below to participate and receive ongoing education and support at no cost to you. (Please see reverse side for full Authorization.)							
☐ By checking this box and signing below, I provide my authorization to the Patient Authorization for the use and disclosure of personal health information							
☐ By checking this box and signing below, I confirm understanding of the Patient Authorization and Registration for optional supplemental education and support programs available for patients prescribed Acthar.							
Patient Signature - Patient, please sign and date below - Please sign ONE LINE below							
PATIENT NAME OR LEGAL REPRESENTATIVE	PATIENT SIGNATURE	IF LEGAL REPRESENTATIVE, RELATIONSHIP TO PAT	IENT DATE				
6. HCP SIGNATURE	sign ONE LINE below						
HCP Prescriber Signature - Please s	sign UNE LINE DEIOW						
DISPENSE AS WRITTEN Prescriber signature required to consent and validate	DATE prescriptions. Prescriber attests that this is her/his sign.	SUBSTITUTIONS ALLOWED	DATE s medically necessary.				



## 5. PATIENT AUTHORIZATION(S) (CONTINUED FROM REVERSE)

## Patient Authorization for use and disclosure of personal health information

By signing this authorization, I authorize my physician(s), my health insurance company, my pharmacy providers and Mallinckrodt ARD Inc., the distributor of Acthar ("Mallinckrodt"), its agents, authorized designees and contractors, including Avella Specialty Pharmacy ("Avella") (Avella, together with Mallinckrodt and its agents, "Designated Parties"), to use and disclose to Designated Parties health information relating to my medical condition, treatment, and insurance coverage (my "Health Information") in order for them to (1) provide certain services to me, including reimbursement and coverage support, patient assistance and access programs, medication shipment tracking, and home injection training, (2) provide me with other educational and support services associated with Acthar therapy, (3) contact me about participation in Acthar patient programs, (4) for the Acthar Support and Access Program's proper management and administration and for Mallinckrodt to carry out its legal responsibilities, (5) for internal business purposes, such as for marketing research, internal financial reporting and operational purposes.

Once my Health Information has been disclosed to the Designated Parties, I understand that it may be redisclosed by them as permitted by this authorization or as otherwise permitted or required by law and will no longer be protected by federal and state privacy laws. However, the Designated Parties agree to protect my Health Information by using and disclosing it only for the purposes authorized in this authorization or as permitted or required by law.

I understand that I may refuse to sign this authorization and that my physician and pharmacy will not condition my treatment on my agreement to sign this authorization form, and my health plan or health insurance company will not condition payment for my treatment, insurance enrollment or eligibility for insurance benefits on my agreement to sign this authorization form. I understand that my pharmacies and Designated Parties may receive payment in connection with the disclosure of my Health Information as provided in this authorization. I understand that I am entitled to receive a copy of this authorization after I sign it.

I may revoke (withdraw) this authorization at any time by mailing a letter to 23620 N. 20th Drive, Suite 12, Phoenix, AZ 85085. Revoking this authorization will end further disclosure of my Health Information to Designated Parties by my pharmacy, physicians and health insurance company when they receive a copy of the revocation, but it will not apply to information they have already disclosed to the Designated Parties based on this authorization.

This authorization is in effect for 1 year once I have signed it unless I cancel it before then. I understand I do not have to sign this form. It plays no role in getting my medicine.

## Patient Authorization and Registration for optional supplemental education and support programs available for patients prescribed Acthar (Continued from reverse)

Specifically, I authorize Mallinckrodt and its agents to (1) contact me about participation in Acthar patient programs, (2) provide me with educational or information materials, (3) administer its education and support programs appropriately, (4) conduct surveys that request my feedback, and (5) for Mallinckrodt to carry out its legal responsibilities. I agree to let Mallinckrodt or its agents contact me in the future about these offerings. However, Mallinckrodt and its agents agree to protect my Health Information by using and disclosing it only for the purposes described in this authorization or as permitted or required by law.

I also know I may cancel my enrollment in a patient support program at any time by contacting Mallinckrodt at 25125 Santa Clara St. #E287, Hayward, CA 94544-2109. If I withdraw my permission, I know that this means I may no longer receive information on supplemental education programs. Once I withdraw my permission, no new information will be disclosed to Mallinckrodt or its agents, but Mallinckrodt and its agents may continue to use the information that was collected before I withdrew my permission as permitted by this authorization or as otherwise permitted or required by law.

7. DIAGNOSIS AND ME	DICAL INFORMATION						
	DICAL INI ONMATION						
Diagnosis	d						
_	d responses to associated qu	uestions					
☐ Keratitis			Optic Neuritis				
☐ Iritis			☐ Anterior Segment Inflammation				
☐ Iridocyclitis			☐ Chorioretinitis				
☐ Uveitis			☐ Other diagnosis				
☐ Choroiditis							
8. RELEVANT TREATMENT HISTORY							
Therapy Name	Dose	Start Dat	te	Stop Date (if applicable)	Clinical Comments (eg, type of outcome)		
9. HISTORY OF CORTIC	COSTEROID USE (IF APP	LICABLE)					
Please check all that apply	,						
	with the following response(	(s):	A corticosteroid	was not tried due to the foll	owing response(s):		
☐ Patient hypersensitive or allergic			☐ Corticosteroid use is contraindicated for this patient				
☐ Patient intolerant to corticosteroids OR		OR	☐ Patient has known intolerance to corticosteroids				
☐ Corticosteroid use failed, expected with Acthar	but same response not			cess is not possible for this p			
Other:			Other:	☐ Other:			
U Other.							
HCP SIGNATURE: REQ	UIRED FOR DOCUMENTA	ATION					
NAME			SIGNATURE		DATE		
IMPORTANT NOTICE: This fax is intended to be delivered only to the named addressee and contains confidential information that may be protected health information							
	under federal and state laws. If you are not the intended recipient, do not disseminate, distribute, or copy this fax. Please notify the sender immediately if you have						
					s permitted per order form. Please use		
a new form for additional items							

3

For Patient:

DOB:

Acthar Support and Access FAX: 1-877-221-9505 TEL: 1-877-463-8803

